222 related articles for article (PubMed ID: 37394895)
1. Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months.
van der Lans RJL; Otten JJ; Adriaensen GFJPM; Hoven DR; Benoist LB; Fokkens WJ; Reitsma S
Allergy; 2023 Oct; 78(10):2684-2697. PubMed ID: 37394895
[TBL] [Abstract][Full Text] [Related]
2. Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference?
Al-Ahmad M; Ali A; Khalaf M; Alterki A; Rodriguez-Bouza T
BMC Pulm Med; 2023 Jul; 23(1):266. PubMed ID: 37464395
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
4. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real-life study (DUPIREAL).
De Corso E; Pasquini E; Trimarchi M; La Mantia I; Pagella F; Ottaviano G; Garzaro M; Pipolo C; Torretta S; Seccia V; Cantone E; Ciofalo A; Lucidi D; Fadda GL; Pafundi PC; Settimi S; Montuori C; Anastasi F; Pagliuca G; Ghidini A; Cavaliere C; Maffei M; Bussu F; Gallo S; Canevari FRM; Paludetti G; Galli J;
Allergy; 2023 Oct; 78(10):2669-2683. PubMed ID: 37203259
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps.
Dharmarajan H; Falade O; Lee SE; Wang EW
Int Forum Allergy Rhinol; 2022 Aug; 12(8):986-995. PubMed ID: 34919344
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.
De Prado Gomez PharmD MSc L; Khan Mbbs Mph AH; Peters Md AT; Bachert Md PhD C; Wagenmann Md M; Heffler Md PhD E; Hopkins BMBCh C; Hellings Md PhD PW; Zhang PhD M; Xing PhD J; Rowe Md P; Jacob-Nara Md Mph DHSc JA
Am J Rhinol Allergy; 2022 Nov; 36(6):788-795. PubMed ID: 35837739
[TBL] [Abstract][Full Text] [Related]
7. Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps.
Pelaia C; Benfante A; Busceti MT; Caiaffa MF; Campisi R; Carpagnano GE; Crimi N; D'Amato M; Foschino Barbaro MP; Maglio A; Minenna E; Nolasco S; Paglino G; Papia F; Pelaia G; Portacci A; Ricciardi L; Scichilone N; Scioscia G; Triggiani M; Valenti G; Vatrella A; Crimi C
Front Immunol; 2023; 14():1121237. PubMed ID: 37063895
[TBL] [Abstract][Full Text] [Related]
8. Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps.
Kilty SJ; Lasso A
J Otolaryngol Head Neck Surg; 2022 Apr; 51(1):17. PubMed ID: 35468866
[TBL] [Abstract][Full Text] [Related]
9. A prospective study on the efficacy of dupilumab in chronic rhinosinusitis with type 2 inflammation.
Trimarchi M; Vinciguerra A; Rampi A; Tanzini U; Nonis A; Yacoub MR; Bussi M
Acta Otorhinolaryngol Ital; 2022 Dec; 42(6):538-544. PubMed ID: 36654520
[TBL] [Abstract][Full Text] [Related]
10. [Chronic rhinosinusitis with nasal polyps-extension of dupilumab treatment intervals].
Appel HM; Lochbaum R; Hoffmann TK; Hahn J
HNO; 2024 Jul; 72(7):499-503. PubMed ID: 38761229
[TBL] [Abstract][Full Text] [Related]
11. Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience.
Galletti C; Ragusa M; Sireci F; Ciodaro F; Barbieri MA; Giunta G; Grigaliute E; Immordino A; Lorusso F; Dispenza F; Freni F; Galletti F; Gallina S; La Mantia I; Galletti B
Am J Otolaryngol; 2024; 45(1):104106. PubMed ID: 37948824
[TBL] [Abstract][Full Text] [Related]
12. Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis.
Bachert C; Hellings PW; Mullol J; Hamilos DL; Gevaert P; Naclerio RM; Joish VN; Chao J; Mannent LP; Amin N; Abbe A; Taniou C; Fan C; Pirozzi G; Graham NMH; Mahajan P; Staudinger H; Khan A
Allergy; 2020 Jan; 75(1):148-157. PubMed ID: 31306495
[TBL] [Abstract][Full Text] [Related]
13. Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps.
Scangas GA; Wu AW; Ting JY; Metson R; Walgama E; Shrime MG; Higgins TS
Laryngoscope; 2021 Jan; 131(1):E26-E33. PubMed ID: 32243622
[TBL] [Abstract][Full Text] [Related]
14. Dupilumab improves sleep quality in chronic rhinosinusitis with nasal polyps.
Riva G; Garetto M; Borgione M; Piazza F; Prizio C; Dellea D; Albera A; Canale A; Pecorari G
Am J Otolaryngol; 2024; 45(4):104310. PubMed ID: 38677148
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report.
Orlando P; Licci G; Kuitche D; Matucci A; Vultaggio A; Gallo O; Maggiore G
Eur Arch Otorhinolaryngol; 2024 Mar; 281(3):1317-1324. PubMed ID: 37910208
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.
Mullol J; Laidlaw TM; Bachert C; Mannent LP; Canonica GW; Han JK; Maspero JF; Picado C; Daizadeh N; Ortiz B; Li Y; Ruddy M; Laws E; Amin N
Allergy; 2022 Apr; 77(4):1231-1244. PubMed ID: 34459002
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab (Dupixent
Jansen F; Becker B; Eden JK; Breda PC; Hot A; Oqueka T; Betz CS; Hoffmann AS
Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1741-1755. PubMed ID: 36242612
[TBL] [Abstract][Full Text] [Related]
18. The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP).
Hardison SA; Senior BA
J Otolaryngol Head Neck Surg; 2023 Sep; 52(1):64. PubMed ID: 37759322
[TBL] [Abstract][Full Text] [Related]
19. Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps.
Mullol J; Bachert C; Amin N; Desrosiers M; Hellings PW; Han JK; Jankowski R; Vodicka J; Gevaert P; Daizadeh N; Khan AH; Kamat S; Patel N; Graham NMH; Ruddy M; Staudinger H; Mannent LP
J Allergy Clin Immunol Pract; 2022 Apr; 10(4):1086-1095.e5. PubMed ID: 34628065
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab improvements in health-related quality of life and disease symptoms in a patient population with very severe chronic rhinosinusitis with nasal polyps: psychometric and efficacy analyses from the SYNAPSE study.
Fokkens W; Trigg A; Lee SE; Chan RH; Diamant Z; Hopkins C; Howarth P; Lund V; Mayer B; Sousa AR; Yancey S; Tabberer M;
J Patient Rep Outcomes; 2023 Jan; 7(1):4. PubMed ID: 36662344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
